Dr. Santosh Kumar

Associate Professor

Work Experience

I possess extensive experience and expertise in the field of cancer biology and cell therapy, having worked in various prestigious institutions worldwide. Presently, I serve as an Associate Professor at Guru Ghasidas Vishwavidyalaya, Bilaspur (C.G.), where I continue my research in cancer and cell therapy, starting from 8th May 2023. Prior to this, I held the position of a Research Scientist at MD Anderson Cancer Center, Houston, Texas, USA, from 16 May 2022 to 31st April 2023. During this tenure, my research focused on IPSC-derived cell therapy systems and their integration with genomics. I had the privilege of being a Ramanujan Fellow at both AIIMS Patna, India, and Panjab University, Chandigarh, India, from January 2017 to July 2021. My research during this period was centered around understanding the role of TG2 in drug resistance and metastasis in cancer. Before that, I served as a Post-Doctoral Fellow at the University of Houston from December 2014 to March 2016, conducting research on SUMOylation and its implications in cancer. Moreover, as a Postdoc Research Fellow at the University of Mississippi Medical Center from August 2013 to December 2014, I delved into the intricacies of muscle wasting and aging in relation to cancer. My research journey also included various Postdoctoral Fellow positions at MD Anderson Cancer Center, Houston, Texas, USA (Apr 2013 to Aug 2013) and (June 2010 to Apr 2012), where I focused on drug resistance, EMT, and metabolism in cancer. Additionally, I was a Postdoctoral Associate at Baylor College of Medicine from Apr 2012 to Apr 2013, researching the role of mitochondria in cancer. At Nebraska Medical Center, Omaha, NE, USA, I served as a Postdoctoral Research Associate from Apr 2009 to Jun 2010, working on the regulation of p66Shc in prostate cancer. Through these diverse roles, I have made significant contributions to cancer research and therapy, with a commitment to advancing scientific knowledge and improving patient outcomes.

Area of Specialization

Area of Interest/Specialization: iPSC Derived Cell Therapy, Cancer Metastasis, Cancer Metabolism, EMT, CAR T cells, Hippo Signaling, Cancer Cachexia, Diabetes. Experience: Research: 19 years

Projects & Patents

PROJECT: Targeting Transglutaminase 2 (TGM2) and Hypoxia-inducible factor 1 alpha (HF1?) to reverse chemoresistance and metastasis Duration: 2016-07-14 2021-07-13 SERB/DBT Total amount Rs. 1,07,22, 467 PATENT Anti-tumor activity of AECHL-1, a novel triterpenoid isolated from Ailanthus excelsa in vitro and in vivo. Dr. Sandhya Sitasawad, Manish S. Lavhale, Santosh Kumar and Dr. Shri Hari Mishra. [Indian patent (2261/DEL/2008), international PCT application no. (PCT/IN08/000795) US patent US 8519163B2, European patent EP 2337782B1.

Education

M.Sc. Biotechnology: Kuman University Nainital, Ph.D. Diabetes Cardiomyopathy: National Center for Cell Science, Pune

Achievments/Awards/Honors

Ramanujan Fellowship Fellow 2015 Biological Science CSIR-UGC NET 2004 December Life science CSIR-UGC NET 2003 December Life science ICMR 2003 Life science GATE 2003 Life science

Publications

LIST OF PUBLICATIONS 1. Design, synthesis and anticancer activity of 2-arylimidazo[1,2-a] pyridinyl-3-amines. Yadav UP, Arshad J.Ansari JA, Arora S, Joshi G, Singh T, Kaur H, Dogra N, Kumar R Kumar Santosh, Sawant DM, Singh S. Bioorganic Chemistry. 2022 Jan; 118:105464. Corresponding Author, Impact Factor- 5.307 2. Let-7a induces metabolic reprogramming in breast cancer cells via targeting mitochondrial encoded ND4. Sharma P, Sharma V, Singh T, Ahluwalia, Dogra N, Kumar Santosh, Singh S. Cancer Cell Int. 2021 Nov 27;21(1):629. Impact Factor- 6.436 3. Yadav UP, Singh T, Kumar P, Sharma P, Kaur H, Sharma S, Singh S, Kumar Santosh and Mehta K. Metabolic Adaptations in Cancer Stem Cells. Frontiers in oncology. 2020 June, 25;10:1010. Corresponding Author, Impact Factor- 5.738. 4. Yadav RK, Ali A, Kumar Santosh, Sharma A, Baghchi B, Singh P, Das S, Singh C, Sharma S. CAR T cell therapy: newer approaches to counter resistance and cost. Heliyon 6 (2020) e03779. Impact Factor- 3.776 5. Joshi G, Ansari A J, Yadav U, Singh S, Sawant D, Singh P, Sharma P, Amrutkar S, Banerjee U, Sharon A, Kumar Santosh, Sharma S, Kalra S and Kumar R. E-pharmacophore Enabled Screening of Pyrazolo[1,5-c]quinazolines as Non-camptothecin Topoisomerase-I Inhibitors: Synthesis, Anticancer Evaluation and Their Further Preliminary Assessment as Dual Topoisomerase-I and Histone Deacetylase. Bioorganic Chemistry. 2020 Jan; 94:103409. Impact Factor- 5.307 6. Parash Parajuli, Santosh Kumar, Audrey Loumaye, Purba Singh, Sailaja Eragamreddy, Thien Ly Nguyen, Seval Ozkan, Mohammed S. Razzaque, Ce´ line Prunier, Jean-Paul Thissen, Azeddine Atfi Twist1 Activation in Muscle Progenitor Cells Causes Muscle Loss Akin to Cancer Cachexia. Developmental Cell. 2018 Jun 18;45(6):712-725 Foot note: Santosh Kumar and Parash Parajuli. contribute equally towards this work. Impact Factor- 13.42 7. Karami S, Lin MF, Kumar Santosh, Bahnassy S, Quttina M, Li Y, Ren J, Tasneem Bawa-Khalfe. Novel SUMO-Protease SENP7S Regulates β-catenin Signaling and Mammary Epithelial Cell Transformation. scientific reports. 2017 Apr 21; 7:46477 Impact Factor- 4.996 8. Lin MF, Kumar Santosh, Ren J, Karami S, Bahnassy S, Li Y, Zheng X, JWang J, Tasneem Bawa-Khalfe. SUMOylation of HP1α Supports Association with ncRNA to Define Responsiveness of Breast Cancer Cells to Chemotherapy. Oncotarget. 2016 May 24;7(21) 9. Park JH, Vithayathil S, Kumar Santosh, Sung PL, Dobrolecki LE, Putluri V, Bhat V, Bhowmik S, Gupta V, Arora K, Wu D, Tsouko E, Zhang Y, Maity S, Donti TR, Graham BH, Frigo DE, Coarfa C, Yotnda P, Putluri N, Lewis MT, Sreekumar A, Creighton CJ, Wong C LJ & Kaipparettu BA. Fatty acid beta-oxidation driven Src mediated oncogenic properties links mitochondrial energy reprogramming in the regulation of cancer phenotype in triple negative breast cancer. Cell Reports. 2016 Mar 8;14(9):2154-65 Impact Factor- 9.995 10. Courivaud T, Ferrand N, Elkhattouti A, Kumar Santosh, Levy L, Ferrigno O, Atfi A, and Prunier C. Functional characterization of a WWP1/Tiul1 tumor-derived mutant reveals a paradigm of its constitutive activation in human cancer. Journal of Biological Chemistry. 2015 Aug 21;290(34):21007-18 Impact Factor- 5.485 11. Prunier C, Zhang MZ, Kumar Santosh, Levy L, Ferrigno O, Tzivion G, Atfi A. Disruption of the PHRF1 Tumor Suppressor Network by PML-RARα Drives Acute Promyelocytic Leukemia Pathogenesis. Cell Reports. 2015 Feb 11. pii: S2211-1247(15)00049-2. Impact Factor- 9.995 12. Amy Han, Santosh Kumar, Jansina Y. Fok, Amit K. Tyagi and Kapil Mehta. Tissue transglutaminase expression promotes castration-resistant phenotype and transcriptional repression of androgen receptor. European J of Cancer. 2014 Jun; 50 (9):1685-96. Impact Factor- 10.002 13. Santosh Kumar, Taraka R. Donti, Navneet Aganihotri, Kapil Mehta. Transglutaminase 2 reprograms glucose metabolism in mammary epithelial cells by activating inflammatory signaling pathways. International Journal of Cancer. 2014 Jun 15;134 (12):2798-807. Impact Factor- 7.316 14. Santosh Kumar and Sandhya L. Sitasawad. Multiple antioxidants improve cardiac complications and inhibit cardiac cell death in streptozotocin-induced diabetic rats. PLoS One. 2013 Jul 2;8(7):e67009. Impact Factor- 3.752 15. Navneet Agnihotri, Santosh Kumar and Kapil Mehta. Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast cancer research. 2013 Feb 25;15(1):202. Impact Factor- 8.408 16. Santosh Kumar and Kapil Mehta. Tissue transglutaminase, inflammation, and cancer: how intimate is the relationship? Amino Acids. 2013 Jan;44(1):81-8. Impact Factor- 3.789 17. Santosh Kumar and Kapil Mehta. Tissue Transglutaminase Constitutively Activates HIF-1α Promoter and Nuclear Factor-κB via a Non-Canonical Pathway. PLoS One. 2012;7(11):e49321. Impact Factor- 3.752 18. Anupam Kumar, Jia Xu, Bokyung Sung, Santosh Kumar, Dihua Yu, Bharat B. Aggarwal and Kapil Mehta. Evidence that GTP-binding domain but not catalytic domain of transglutaminase 2 is essential for epithelial-to-mesenchymal transition in mammary epithelial cells. Breast Cancer Res 2012 Jan 6; 14(1):R4. Impact Factor- 8.408 19. Santosh Kumar, Satyendra Kumar, Mythilypriya Rajendran, Syed Mahfuzul Alam, Fen-Fen Lin, Pi-Wan Cheng, Ming-Fong Lin, Steroids up-regulate p66Shc longevity protein in growth regulation by inhibiting its proteasomal degradation pathway. PLoS One. 2011 Jan 14;6(1): e15942. Impact Factor- 3.752 20. Santosh Kumar and Sandhya L. Sitasawad. N-Acetyl Cysteine prevents glucose/glucose oxidase-induced oxidative stress, mitochondrial damage and apoptosis in H9c2 cells. Life Science. 2009 Mar 13; 84(11-12):328-36. Impact Factor- 6.78 21. Murugavel P, Pari L, Sitasawad SL, Kumar S, Santhosh Kumar. Cadmium induced mitochondrial injury and apoptosis in Vero cells: Protective effect of diallyl tetrasulfide from garlic. International Journal of Biochemistry & Cell Biology 2007, 39, 161–170. Impact Factor- 5.652 Book Chapter 1. Kapil Mehta & Santosh Kumar, TG2 – Player that Dictates the Rules in Cancer Progression. Title of the Book: Multi-Targeted Approach to Treatment of Cancer. Publisher & ISBN: Springer International Publishing Switzerland: 978-3-319-12252-6, 2014. 2. Natural Compound-Based Nanoparticles to Target Free Radicals in Cancer. Umesh Prasad Yadav UP, Rhuthuparna M, Vasudev K, Suman P, Munshi A, Santosh Kumar, Singh S. Book: Springer in Nature, Handbook of Oxidative Stress in Cancer: Therapeutic Aspects pp 1-14, 2022 Corresponding Author